Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2010

01.06.2010 | Epidemiology

Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer

verfasst von: Sujee Jeon, Ji-Yeob Choi, Kyoung-Mu Lee, Sue K. Park, Keun-Young Yoo, Dong-Young Noh, Sei-Hyun Ahn, Daehee Kang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer development is related to genes regulating cell cycle progression such as CCND1, CDK7, and ESR1. We conducted a hospital-based case–control study to evaluate the role of genetic polymorphisms in these genes in breast cancer development among Korean women. Questionnaire data and samples were obtained from 864 incident breast cancer cases and 723 controls recruited from 1995 to 2002. Four single nucleotide polymorphisms (SNPs) in three genes were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry [CCND1 Ex4-1G>A (rs9344), CDK7 Ex2-28C>T (rs2972388), ESR1 P325P Ex4-122G>C (rs1801132), and ESR1 T594T Ex8+229G>A (rs2228480)], and their associations with breast cancer risk were assessed. The odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by unconditional logistic regression analysis adjusted for age, education, age at the first full-term pregnancy, and family history of breast cancer. Women carrying the CDK7 TT genotype had increased risk of breast cancer (OR, 1.4; 95% CI, 1.1–1.7). There was no significant association between breast cancer risk and the genetic polymorphisms of CCND1 and ESR1. However, when CDK7 and ESR1 P325P were combined, women carrying both the CDK7 TT and ESR1 P325P CC genotypes showed increased breast cancer risk (OR, 1.7; 95% CI, 1.1–2.5; P for trend, <0.01). In conclusion, our findings suggest that the combined genotypes of CDK7 and ESR1 are associated with breast cancer risk among Korean women.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Deshpande A, Sicinski P, Hinds PW (2005) Cyclins and cdks in development and cancer: a perspective. Oncogene 24(17):2909–2915CrossRefPubMed Deshpande A, Sicinski P, Hinds PW (2005) Cyclins and cdks in development and cancer: a perspective. Oncogene 24(17):2909–2915CrossRefPubMed
2.
Zurück zum Zitat Nakayama KI, Nakayama K (2006) Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6(5):369–381CrossRefPubMed Nakayama KI, Nakayama K (2006) Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6(5):369–381CrossRefPubMed
3.
Zurück zum Zitat Wang J et al (2007) Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res Treat 106(2):273–280CrossRefPubMed Wang J et al (2007) Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res Treat 106(2):273–280CrossRefPubMed
4.
Zurück zum Zitat Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631–643CrossRefPubMed Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631–643CrossRefPubMed
5.
Zurück zum Zitat Shu XO et al (2005) Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 14(1):91–97PubMed Shu XO et al (2005) Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 14(1):91–97PubMed
6.
Zurück zum Zitat Bartkova J, Zemanova M, Bartek J (1996) Expression of CDK7/CAK in normal and tumour cells of diverse histogenesis, cell-cycle position and differentiation. Int J Cancer 66(6):732–737CrossRefPubMed Bartkova J, Zemanova M, Bartek J (1996) Expression of CDK7/CAK in normal and tumour cells of diverse histogenesis, cell-cycle position and differentiation. Int J Cancer 66(6):732–737CrossRefPubMed
7.
Zurück zum Zitat Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9(3):153–166CrossRefPubMed Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9(3):153–166CrossRefPubMed
8.
Zurück zum Zitat Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501–1512CrossRefPubMed Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501–1512CrossRefPubMed
9.
Zurück zum Zitat Castro-Rivera E, Samudio I, Safe S (2001) Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 276(33):30853–30861CrossRefPubMed Castro-Rivera E, Samudio I, Safe S (2001) Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 276(33):30853–30861CrossRefPubMed
10.
Zurück zum Zitat Lu C et al (2009) CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 116(3):571–575CrossRefPubMed Lu C et al (2009) CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 116(3):571–575CrossRefPubMed
11.
Zurück zum Zitat Cortessis VK et al (2003) A case-control study of cyclin D1 CCND1 870A->G polymorphism and bladder cancer. Carcinogenesis 24(10):1645–1650CrossRefPubMed Cortessis VK et al (2003) A case-control study of cyclin D1 CCND1 870A->G polymorphism and bladder cancer. Carcinogenesis 24(10):1645–1650CrossRefPubMed
12.
Zurück zum Zitat Wong YK et al (2003) Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J Oral Pathol Med 32(5):265–270PubMed Wong YK et al (2003) Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J Oral Pathol Med 32(5):265–270PubMed
13.
Zurück zum Zitat Onay U et al (2008) Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 8(1):6CrossRefPubMed Onay U et al (2008) Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 8(1):6CrossRefPubMed
14.
Zurück zum Zitat Tapper W et al (2008) The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res 10(6):R108CrossRefPubMed Tapper W et al (2008) The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res 10(6):R108CrossRefPubMed
15.
Zurück zum Zitat Fernández LP et al (2006) Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study. Int J Cancer 119(2):467–471CrossRefPubMed Fernández LP et al (2006) Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study. Int J Cancer 119(2):467–471CrossRefPubMed
16.
Zurück zum Zitat Einarsdottir K et al (2008) ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 10(1):R15CrossRefPubMed Einarsdottir K et al (2008) ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 10(1):R15CrossRefPubMed
17.
Zurück zum Zitat Lee KM et al (2005) Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res 11(12):4620–4626CrossRefPubMed Lee KM et al (2005) Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res 11(12):4620–4626CrossRefPubMed
18.
Zurück zum Zitat Choi JY et al (2005) Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 14(5):1090–1095CrossRefPubMed Choi JY et al (2005) Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 14(5):1090–1095CrossRefPubMed
19.
Zurück zum Zitat Yu CP et al (2008) Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat 107(1):95–102CrossRefPubMed Yu CP et al (2008) Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat 107(1):95–102CrossRefPubMed
20.
Zurück zum Zitat Curran JE et al (2001) Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer. Int J Cancer 95(4):271–275CrossRefPubMed Curran JE et al (2001) Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer. Int J Cancer 95(4):271–275CrossRefPubMed
21.
Zurück zum Zitat Vasconcelos A et al (2002) Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: association with lymph node metastasis. Breast J 8(4):226–229CrossRefPubMed Vasconcelos A et al (2002) Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: association with lymph node metastasis. Breast J 8(4):226–229CrossRefPubMed
22.
Zurück zum Zitat Akisik E, Dalay N (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76(3):260–263CrossRefPubMed Akisik E, Dalay N (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76(3):260–263CrossRefPubMed
23.
Zurück zum Zitat Larochelle S et al (2006) Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics. Nat Struct Mol Biol 13(1):55–62CrossRefPubMed Larochelle S et al (2006) Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics. Nat Struct Mol Biol 13(1):55–62CrossRefPubMed
24.
Zurück zum Zitat Chen D et al (2002) Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21(32):4921–4931CrossRefPubMed Chen D et al (2002) Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21(32):4921–4931CrossRefPubMed
25.
Zurück zum Zitat Beato M, Herrlich P, Schutz G (1995) Steroid hormone receptors: many actors in search of a plot. Cell 83(6):851–857CrossRefPubMed Beato M, Herrlich P, Schutz G (1995) Steroid hormone receptors: many actors in search of a plot. Cell 83(6):851–857CrossRefPubMed
Metadaten
Titel
Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer
verfasst von
Sujee Jeon
Ji-Yeob Choi
Kyoung-Mu Lee
Sue K. Park
Keun-Young Yoo
Dong-Young Noh
Sei-Hyun Ahn
Daehee Kang
Publikationsdatum
01.06.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0640-6

Weitere Artikel der Ausgabe 3/2010

Breast Cancer Research and Treatment 3/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.